Affinity Selection Mass Spectrometry

Our dedicated ASMS (Affinity Selection Mass Spectrometry) screening team offers clients this unique platform for the identification of small molecules capable of binding to the active sites of target proteins. These active small molecules will be the perfect starting point for your drug discovery programs. Our high quality service supports both established and newly emerging targets and is backed by access to small molecule libraries, automated operational systems, sensitive high resolution mass spectrometry devices and efficient data processing software. 

ASMS workflow at WuXi AppTec

Hit identification within 6 weeks

ASMS, affinity selection mass spectrometry screening with unique libraries and target proteins

Capability and Advantages

Our experts’ experience in ASMS screening: served 28 clients, screened 24 targets (size from 12KDa – 400KDa), and screened over 3 million compounds.

ASMS, affinity selection mass spectrometry, HRMS, high resolution and sensitivity, biophysics

Unique Libraries and Target Proteins

ASMS Libraries

Our collection is greater than 535,000 compounds available for hit expansion.

  • WuXi AppTec designed library (available for sale)
  • Biotech derived (exclusive)
  • Commercial vendors
  • Purified natural products or extracts
  • Library of pharmacologically active compounds
  • LOPAC, Prestwick
  • Majority semi-exclusive, non-commercially available.
  • Selected and curated by experienced medicinal chemists.
  • Quality controlled by MS (1% of the collection, randomly picked)
  • Arrayed in 384 & 1536-well plates ready for HTS.
  • Solution stocks available in Shanghai.
ASMS, soluble targets, library mixtures, novel binding pockets, high throughput, scalable, target-SM

Target Proteins

Protein

Aurora A

AKT1

LSD1

BRD3(BD1)

CA2

AKT2

AURKB

BRD3(BD2)

cMET

AKT3

FAK

FXR

Src

IRAK4

GSK3B

PTK1

Glycolate Oxidase

PDL1

JNK1

PTK2

BRD4

HSP90a

PLK1

LRRK2

HSP90b

SYK

IL2

STING

TRKC

DPP4

CHK1

CDK2

IDO1

CHK2

ASK1

TDO2

PI3K gamma

BRD2(BD1)

MAPKAPK2

p38 alpha

BRD2(BD2)

Flexible Collaboration Models

Choices

Target protein

Small molecule library

1

WuXi

WuXi

2

WuXi

Clients

3

Clients

WuXi

4

Clients

Clients

Capability: Current instrument setting can ensure screen 160,000-200,000 molecules in one month.

Watch the webinar: The Evolving Role of Mass Spectrometry in Drug Discovery